Wanbury Ltd Completes First Shipment of New Anaesthetic API
Filing Summary
Wanbury Ltd announced the completion of its first sales invoicing and commercial shipment for a new high-demand anaesthetic Active Pharmaceutical Ingredient (API) on January 30, 2026. This milestone marks the commencement of production ramp-up at its Tanuku facility. The company has secured orders from European customers, confirming operational capabilities and product quality. Wanbury Ltd, listed on the BSE and NSE, specializes in APIs and branded formulations, exporting to over 50 countries. The company aims to enhance its market presence in the pharmaceutical sector.
Wanbury Ltd has completed its first sales invoicing and commercial shipment for a new high-demand anaesthetic Active Pharmaceutical Ingredient (API) on January 30, 2026. This milestone signifies the beginning of the production ramp-up at the company’s Tanuku facility. The shipment was made to European customers, marking a significant step in Wanbury’s operational expansion.
The financial terms of the shipment were not disclosed in the filing. However, the completion of this milestone indicates that Wanbury Ltd has secured orders from international clients, which confirms the company’s operational capabilities and product quality. The company has not provided specific revenue figures related to this shipment.
The scope of the shipment involves the production and delivery of a newly commercialized anaesthetic API. The Tanuku facility, which is USFDA and EUGMP approved, is responsible for the manufacturing of this product. The facility’s capabilities include the production of various APIs, including Metformin, Sertraline, and Tramadol, among others. The shipment to European customers demonstrates Wanbury’s ability to meet global demand and adhere to international quality standards.
The market context for this shipment is significant, as Wanbury Ltd is a key player in the Active Pharmaceutical Ingredients (API) sector. The company exports its products to over 50 countries and has a strong presence in both the global and domestic markets. The completion of this shipment aligns with Wanbury’s strategy to expand its market presence and enhance its product offerings in the pharmaceutical industry.
The timeline for the production ramp-up at the Tanuku facility began with the shipment on January 30, 2026. This milestone was achieved just months after the initial launch of the new anaesthetic API. The company has not disclosed specific future timelines for additional shipments or production increases.
**About Wanbury Ltd**: Established in 1988, Wanbury Ltd is listed on the BSE and NSE. The company specializes in Active Pharmaceutical Ingredients and branded formulations, with a strong presence in the global market. Wanbury exports its products to over 50 countries and operates USFDA and EUGMP approved facilities in Tanuku and Patalganga. The company’s product portfolio includes APIs such as Metformin, Sertraline, and Tramadol, catering to various therapeutic categories.